Novo Presents Cagrisema Data Ahead of FDA Decision
Published 16 h ago2 sourcesEvidence: Reported
Experts warn that newer GLP-1 drugs for obesity will spark a global access fight, mirroring past battles over HIV and COVID treatments. The high cost and limited supply of these drugs could exacerbate health inequities in lower-income countries. The outcome will depend on pricing, patent policies, and international pressure.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 16 h ago2 sourcesEvidence: Reported
Published 8 h ago1 sourceEvidence: Reported
Published 12 h ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 17 h ago2 sourcesEvidence: Reported
Published 8 h ago2 sourcesEvidence: Reported
Published 29 min ago2 sourcesEvidence: Reported
Published 9 h ago1 sourceEvidence: Reported